Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TARGET-TNBC: Sacituzumab Govitecan, Zimberelimab, and SRS in Metastatic TNBC with Brain Metastases
NCT06238921Phase 2Recruiting
- Sponsor
- Moffitt Cancer Center
- Start
- Dec 2024
- Primary completion
- Feb 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of zimberelimab and sacituzumab govitecan in triple-negative breast cancer (TNBC) and brain metastases, sponsored by Moffitt Cancer Center. Primary endpoints: Neurologic Toxicity at 9 weeks and Progression Free Survival at 12 months. Started Dec 2024; status: recruiting.
02
Drugs
zimberelimabsacituzumab govitecan
03
Conditions
triple-negative breast cancer (TNBC)brain metastases
Beyond the preview
Go deeper on NCT06238921.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06238921.